STOCK TITAN

MBX Biosciences: Paradigm reports 7.8% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

MBX Biosciences, Inc. (MBX) shares are reported as beneficially owned by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D., each reporting 3,772,885 shares, or 7.8%. Paradigm BioCapital International Fund Ltd. separately reports 3,324,531 shares, or 6.9%. The reported positions are as of the close of business September 30, 2026.

The Fund and one or more separately managed accounts directly beneficially own the reported Common Stock. The Adviser, its general partner and Asefaw may be deemed beneficial owners of shares directly owned by those vehicles. Each reporting person disclaims beneficial ownership of shares other than Common Stock directly beneficially owned by that person.

Reported beneficial ownership 3,772,885 shares Each reported by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D.; as of September 30, 2026
Reported ownership percentage 7.8% Reported by Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D.
Fund beneficial ownership 3,324,531 shares Reported by Paradigm BioCapital International Fund Ltd. as of September 30, 2026
Fund ownership percentage 6.9% Reported by Paradigm BioCapital International Fund Ltd.
Common Stock outstanding 48,160,096 shares As of August 3, 2026; used as the basis for the reported ownership percentages
beneficial ownership regulatory
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting power regulatory
"Sole Voting Power"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole Dispositive Power"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MBX shares did Paradigm BioCapital report owning?

Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC and Senai Asefaw, M.D. each reported beneficial ownership of 3,772,885 shares, or 7.8%, as of September 30, 2026.

How many MBX shares did Paradigm BioCapital International Fund report?

Paradigm BioCapital International Fund Ltd. reported beneficial ownership of 3,324,531 shares, or 6.9%, as of September 30, 2026.

Why are multiple reporting persons listed for MBX shares?

The Fund and one or more separately managed accounts managed by Paradigm BioCapital Advisors LP directly beneficially own the reported Common Stock. The Adviser is their investment manager, Paradigm BioCapital Advisors GP LLC is the Adviser's general partner, and Senai Asefaw, M.D. is the managing member of the Adviser GP; they may be deemed beneficial owners of those directly held shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





55287L101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person: limited liability company


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Paradigm BioCapital Advisors LP
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Paradigm BioCapital Advisors GP LLC
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026
Senai Asefaw, M.D.
Signature:/s/ Senai Asefaw, M.D.
Name/Title:N/A
Date:11/16/2026
Paradigm BioCapital International Fund Ltd.
Signature:/s/ David K. Kim
Name/Title:David K. Kim / Authorized Signatory
Date:11/16/2026

Keep reading